JAZZ

#796
Jazz Pharmaceuticals, Inc.
203.4200 USD
+2.83%
Сектор: Здравоохранение
Базовая: USD
Валюта прибыли: USD
Дневной диапазон
203.4200
203.4200
Годовой диапазон
128.8000
203.4200
Дневное изменение
+2.83%
Месячное изменение
+11.33%
6-месячное изменение
+45.30%
Годовое изменение
+45.30%
Предыдущее закрытие
197.8300
Открыть
203.4200
Bid
Ask
Минимум
203.4200
High
203.4200
Объем
84
Открыть полный график

Financials

Обзор Отчетность Статистика
Квартал Год
  • Market Capitalization 12.5226 B
  • Employee 2 890
  • Founded 2003
  • CEO Bruce C Cozadd
  • Website www.jazzpharmaceuticals.com
  • Headquarter Ireland
  • FIGI N/A
  • Industry Биотехнологии
Общий доход
Чистая прибыль
Базовая прибыль на акцию
Общий долг
Свободный денежный поток
Денежные средства и эквиваленты
Коэффициент цена/прибыль
-29.11
Коэффициент цена/денежный поток
2.43

Jazz Pharmaceuticals plc

Jazz Pharmaceuticals plc is an American global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland. One of the company's considerable products is the United States Food and Drug Administration approved drug Xyrem, the sodium salt of the naturally occurring neurotransmitter γ-Hydroxybutyric acid. In 2017, net product sales of Xyrem were $1.187 billion, which represented 74% of the company's total net product sales. In 2019, Jazz was granted FDA-approval to market Sunosi with indications for treating excessive daytime sleepiness in narcolepsy as well as obstructive sleep apnea. In 2022, it was announced that Axsome Therapeutics would be acquiring Sunosi from Jazz Pharmaceuticals. In 2007, the company pled guilty to felony charges related to its illegal marketing of Xyrem for off-label use. The company is also a member of the Pharmaceutical Research and Manufacturers of America.

Новости